These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Infliximab therapy in Behçet's uveitis.
    Author: Alizadegan F, Yalcinbayir O, Ucan Gunduz G, Pehlivan Y.
    Journal: J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991.
    Abstract:
    PURPOSE: To evaluate the efficacy of infliximab (IFX) therapy in patients with Behçet's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT). MATERIALS AND METHODS: This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic characteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study. RESULTS: Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5±25.9months. The mean frequency of recurrences during the IMT was 1.47±0.78 (attacks/year), decreasing to 0.31±0.40 (attacks/year) with IFX (P<0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P=0.026). Partial response to treatment was achieved in 91.4% of cases. CONCLUSION: IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.
    [Abstract] [Full Text] [Related] [New Search]